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Background/ Objectives: There has been growing interest in using dietary intervention to improve the lipid profile. This work
aims at analyzing the effects and the comparison of the enrichment of a diet with beta-glucans or rice bran in mildly
hypercholesterolemic men.
Subjects/Methods: The subjects initially consumed a 3-week Step 1 American Heart Association diet with rice bran-enriched
foods. After this adaptation period, volunteers were randomly assigned to follow a crossover, controlled trial that consisted of
two treatment with beta-glucan- or rice bran-enriched foods, each of 4 weeks, with a 3-week wash-out, like the adaptation
period, between periods. Fasted blood samples were collected on days 0, 21, 49, 70 and 98 in both study arms
for measuring low-density lipoprotein (LDL)-cholesterol (primary outcome), total cholesterol, high-density lipoprotein
(HDL)-cholesterol, triglycerides, apolipoprotein (apo) A-I, apo B and glucose levels.
Results: Twenty-four men (mean age: 50.3±5.3, mean body mass index: 24.9±1.9) completed the 14-week trial. Subjects in
the 3-week adaptation period experienced significant reductions in the mean change of LDL cholesterol, total cholesterol, total
cholesterol/HDL cholesterol, LDL cholesterol/HDL cholesterol, apo A-I, apo A-I/apo B and glucose. During the intervention diet
periods, a difference was found between treatment groups for the mean change in LDL (0.21 (95% confidence interval (CI):
0.02–0.40), P¼0.033) and total cholesterol (0.34 (95% CI: 0.20–0.47), Po0.001). Other parameters evaluated were not
significantly affected by the diet consumed.
Conclusions: The results of the present crossover clinical trial showed that beta-glucan-enriched foods are more effective in
lowering serum LDL levels, compared with rice bran-enriched foods.
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Introduction
Lowering serum cholesterol reduces the risk of coronary
heart disease (National Cholesterol Educational Program,
Adult Treatment Panel III, 2002). The protective effects of
dietary fiber against cardiovascular disease (CVD), mediated
through a reduction in serum lipids, were first reported
440 years ago by Keys et al. (1960); later research led to the
dietary fiber hypothesis proposed by Burkitt et al. (1974) and
Trowell (1975) that states that a high intake of starchy
carbohydrates and fiber is protective against CVD. Many
trials showed a hypocholesterolemic effect of an increased
intake of fiber from cereals, such as barley, rice and oats;
the active component in barley has been identified as
beta-glucans, which reduces serum total cholesterol by
5–10% (according to Anderson, 1987; McIntosh et al.,
1991; Shimizu et al., 2008; Talati et al., 2009) and by 20%
(according to Behall et al., 2004), although not all studies
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(Keogh et al., 2003) showed barley beta-glucans to be
hypocholesterolemic.
Although all the possible mechanisms explaining the
cholesterol-lowering effect of beta-glucans are not well
known, the most likely explanation is that water-soluble
fibers lower the re-absorption of bile acids (Kirby et al., 1981;
Lia et al., 1995). As a result, the hepatic conversion of
cholesterol into bile acids increases and the hepatic pools of
free cholesterol decrease. Consequently, hepatic low-density
lipoprotein (LDL)-cholesterol receptors become upregulated
to re-establish hepatic cholesterol stores, thus promoting a
decrease of serum LDL cholesterol (Reihner et al., 1990).
Moreover, a recent study showed that the reduced intestinal
fatty acid uptake observed with beta-glucans is associated
with the inhibition of genes regulating intestinal uptake and
with synthesis of lipids (Drozdowski et al., 2010).
As regards rice, active components with cholesterol-
lowering effect have been identified in bran and are, over
insoluble fiber, novel compounds such as desmethyl toco-
trienol and didesmethyl tocotrienol (Qureshi et al., 2000),
gamma-oryzanol (Sugano et al., 1999) and polyphenolic
ferulic acid (Wilson et al., 2007).
In recent years, the US Food and Drug Administration has
endorsed the relationship between an increase in soluble
fiber and a decrease in serum total cholesterol by ratifying
health claims for barley (FDA, 2005). Overall, the question as
to whether various types of fibers exert different effects, and
if so to what extent, is not yet conclusive (Brown et al.,
1999); moreover, results from different clinical trials vary
depending on whether dietary fiber is given to volunteers as
a natural ingredient in food sources or as an isolated food
supplement.
Given this background, this study aimed (I) at testing the
effects of beta-glucan-enriched food on lipid pattern in
mildly hypercholesterolemic men and (II) at comparing, in a
crossover clinical trial, the effects of a soluble fiber (beta-
glucans from barley) and an insoluble fiber (bran from rice)
on lipid levels in this population.
Subjects and methods
Subjects
Subjects were recruited from Pavia by advertising in national
newspapers and were screened through a procedure invol-
ving a clinical evaluation, an interview and an estimation
of plasma total and LDL cholesterol levels.
Twenty-four men aged 18–60 years, body mass index
19–30kg/m2, with mild hypercholesterolemia (5.4–7.0mmol/l)
and no history of CVD, volunteered for the trial. The men were
not taking any medication that was likely to affect lipid
metabolism and they were free of overt liver, renal, metabolic
disease such as diabetes and thyroid disease. Screening
excluded men who smoked or drank more than two standard
alcoholic beverages per day (20g per day of alcohol). The
experimental protocol was approved by the Ethics Committee
of the University of Pavia and volunteers gave their written
informed consent.
Before beginning the study, energy and nutrient intakes
of the volunteers were assessed using the food record method
for 3 days. Once the data were collected, the food intake
registered was converted into energy and nutrients using
the Rational Diet (Milan, Italy).
Diets were fed in a crossover manner. The intervention
consisted of an adaptation period (3 weeks) and two diet
periods (beta-glucan- and rice bran-enriched foods, 4 weeks
each), with a wash-out period (3 weeks) in between (Figure 1).
At adaptation and during the wash-out period, subjects
consumed a Step 1 American Heart Association diet (Amer-
ican Heart Association, 1988) consisting of a 7-day rotating
menu enriched with rice bran fiber (on average 30 g per day).
Each week, volunteers were supplied with foods and instruc-
ted to use them within a personalized normocaloric and
balanced diet prepared by a dietitian on the basis of a specific
single subject’s requirement of energy and nutrients. As
regards beta-glucan-enriched foods, every day each subject
consumed 100 g of pasta with beta-glucans, together with
tomato sauce with beta-glucans (100 g), 200 g of vegetable
Adaptation Wash-out
Beta-glucansRice bran
Beta-glucans Rice bran
3 weeks 4 weeks 4 weeks3 weeks
n = 24
n = 12
n = 24
n = 12
n = 12n = 12
Figure 1 Summary of the treatment periods and the study design.
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soup with beta-glucans, 95 g of bread with beta-glucans (four
slices) and 55 g of rice cakes with beta-glucans (seven rice
cakes). As regards rice bran-enriched foods, every day each
subject consumed 100g of whole pasta together with tomato
sauce with rice bran (100 g), 200 g of vegetable soup with rice
bran, 95 g of bread with rice bran (four slices) and 55 g of rice
cakes with rice bran (seven rice cakes).
Intervention foods
Palatable, beta-glucan- or rice bran-enriched foods were
developed and manufactured by Riso Scotti (Pavia, Italy).
The rice pasta with beta-glucans was produced using
91% rice flour, 2% rice germ and 7% Barley Balance
(PolyCell Technologies, Crookston, MI, USA), which is a
type of beta-glucan-enriched barley flour. Barley Balance is a
dry, processed, high-molecular-weight beta-glucan concen-
trate that contains about 30% beta-glucans (method: AOAC
995.16, 18th edn, 2005). Control rice pasta was produced
using 100% whole durum wheat instead of rice flour, rice
germ and Barley Balance.
The rice cakes with beta-glucans were produced using rice
and water, except for replacing 7% of rice with Barley
Balance (6%) and rice germ (1%). Control rice cakes were
prepared replacing 100% Barley Balance with Orybran (Riso
Scotti), a type of rice bran.
The bread with beta-glucans was produced on a laboratory
scale. To obtain 1kg of wheat flour type ‘0’, 0.55 kg of rice
flour, 0.05 kg of rice germ, 0.15 kg of Barley Balance, 1.5 kg of
water, 0.1 kg of rice oil, 0.08 kg of 0.06 dextrose, 0.035 g of
salt and 0.055 yeast were used. The control bread was
produced in the same manner, except for replacing 100%
Barley Balance with Orybran.
The sauces with beta-glucans, packed in single pouches,
were produced by mixing, for each pouch, 71 g of water, 31 g
of tomatoes, 6 g of rice oil, 6 g of Barley Balance, 6 g of mixed
vegetables and 0.5 g of salt. The control sauces were
produced replacing 100% Barley Balance with Orybran.
The cream soups with beta-glucans, packed in a single
pouch, were produced by mixing, for each pouch, 98 g of
water, 95 g of mixed vegetables, 6 g of Barley Balance and
0.5 g of salt. The control cream soups were produced
replacing 100% Barley Balance with Orybran.
The chemical composition of enriched foods is presented
in Table 1.
Nutritional status
Every week, body weight was assessed and body mass index
was calculated. Skinfold thicknesses, assessed following a
standardized technique (Frisancho, 1984), and sagittal
abdominal and waist girth were measured on days 0, 21,
49, 70 and 98.
Health-related quality of life
The studied subjects were tested using the Short-Form
36-Item Health Survey (SF-36) (Ware et al., 1993) in order
to evaluate their quality of life.
The Wexner score for constipation was assessed (Agachan
et al., 1996).
Analyses
Fasted blood samples were collected between 0745 and 1000
hours on days 0, 21, 49, 70 and 98 in both study arms for
measuring direct LDL-cholesterol, total cholesterol, high-
density lipoprotein (HDL)-cholesterol, triglycerides, apolipo-
protein (apo) A-I, apo B and glucose levels. These parameters
were measured enzymatically using an autoanalyzer
(Hitachi, Tokyo, Japan).
Table 1 Nutritional composition of 100 g of foods enriched with beta-glucans or rice bran
Rice pasta
enriched with
beta-glucans
Whole
pasta
Bread rice
enriched with
beta-glucans
Bread rice
enriched
with rice bran
Rice cakes
with beta-
glucans
Rice cakes
with rice
bran
Tomato
sauce with
beta-glucans
Tomato
sauce with
rice bran
Vegetable
soup with
beta-glucans
Vegetable
soup with
rice bran
Energy (kJ) 1459 1429 1142 1159 1515 1652 292 330 150 197
Protein (g) 7.0 12.5 9.8 9.3 9.6 8.8 2.3 2.3 2.8 2.3
Fat (g) 1.9 2.0 4.8 5.3 1.6 3.9 4.1 5.0 0.7 1.6
Saturated fatty
acids (g)
0.8 0.5 1.15 1.27 0.7 1.04 0.98 1.15 0.23 0.73
Carbohydrate (g) 74.7 67.2 45.4 45.1 76.0 77.7 4.2 3.9 3.3 4.6
Complex (g) 70.4 63.7 40.0 42.88 75.7 76.68 0.62 1.06 1.64 3.64
Simple (g) 4.3 3.5 5.4 2.22 0.3 1.02 3.58 2.84 1.66 0.96
Dietary fiber (g) 3.5 7.3 3.3 4.8 4.0 4.6 3.7 4.9 2.6 2.5
Insoluble (g) 2.1 7.1 2.0 3.3 3.0 4.1 2.1 3.9 1.5 2.1
Soluble (g) 1.4 0.2 1.3 1.5 1.0 0.5 1.6 1.0 1.1 0.4
Beta-glucans (g) 1.7 — 1.2 — 1.4 — 1.5 — 0.9 —
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Compliance and palatability
Sensory acceptance of the enriched foods and treatment-
related side effects were assessed at each study visit.
Statistical analysis
Sample size. The difference in levels in LDL-cholesterol after
4 weeks of treatment (primary end point) was used to
compute the sample size of the study. Computations were
based on data from McIntosh et al. (1991). A sample size of
24 will have 80% power to detect a difference of 0.33mmol/l
in means (corresponding to final LDL-cholesterol levels of
4.87mmol/l in control and 4.54mmol/l in treated patients),
assuming a common standard deviation (s.d.) of differences
of 0.54, using a paired Student’s t-test with a 0.050 two-sided
significance level. After accounting for a 10% dropout rate,
we planned to enroll 26 patients per group. Query advisor 4
(Statistical Solutions, Cork, Ireland) was used.
Randomization and masking. A randomly permuted block
randomization list for the two possible sequences was
generated. Masking was guaranteed by identical packages
for both treatments, labeled with A or B according to the
randomization arm.
Analysis of the primary and secondary end points. Descriptive
statistics were computed for each treatment and end point
(mean and s.d. for continuous variables and counts and %
for categorical variables). Mean changes from screening to
baseline and from baseline to the final values of the
considered outcome variables were computed for each arm,
together with their 95% confidence intervals (95% CI), and
assessed with the paired Student’s t-test. For both primary
and secondary end points, the final levels of LDL-cholesterol
(and other biological parameters) were compared between
treatments with a multilevel mixed-effects linear regression
(with a random effect for patients and unstructured
covariance), including also baseline values and period as
covariates. The treatment effect was presented as the mean
difference between final values (95% CI), adjusted for
baseline values and period effect.
A two-sided P-value o0.05 was considered statistically
significant. Stata 11 (StataCorp., College Station, TX, USA)
was used for computation. Post hoc comparisons within
treatments were tested at the 0.025 level (Bonferroni
correction).
Results
Dietary intake and body weight
The nutritional composition of the diets consumed daily by
the volunteers at screening and during the different periods
of the trial is shown in Table 2. Body mass index remained
stable (at screening: 24.92±1.93; at the end of the study:
24.82±2.01).
Cardiovascular risk variables
All the 24 men (mean age: 50.33±5.34) completed the 14-
week trial and their characteristics at the commencement
and at the end of the 3-week adaptation period of the study
are shown in Table 3.
Subjects in the 3-week adaptation period experienced
significant reductions in the mean level of lipid and glucose
parameters (Table 3): the average percentage reduction in
LDL, total cholesterol, apo A-I and glucose was 13, 8, 14 and
3%, respectively.
The effects of intervention diets on cardiometabolic risk
variables are summarized in Table 4. During the intervention
diet periods, a difference of 0.21mmol/l was found between
the treatment groups for the mean change of the primary
end point, which is the LDL-cholesterol (Po0.033); the
decrease was greater in the beta-glucans group than in the
rice bran arm (P¼0.012 and 0.66, respectively): the average
percentage reduction in LDL-cholesterol was 8.6% in the
beta-glucans arm and only 1.1% in the rice bran arm.
Further, a difference was found between the treatment
groups for the mean change of total cholesterol (Po0.001);
the decrease in total cholesterol was significant only in the
beta-glucans group and not in the rice bran arm (P¼0.001
and 0.25, respectively): the average percentage reduction in
total cholesterol was 5.0% in the beta-glucans arm and the
average percentage increase in total cholesterol in the rice
bran arm was 1.3%.
Serum lipid profile and glucose were not significantly
affected by the diet consumed in both groups; hence, no
significant intergroup difference was observed for these
parameters.
Health-related quality of life
As regards the SF-36 score, the results showed that treatment
with beta-glucans did not have a different effect from
treatment with rice bran (Table 4).
The mean changes in the scores of the Wexner scale were
not significantly different in both groups, although the final
score was lower in the latter (Table 4).
Compliance and palatability
Treatment was well tolerated by all subjects, with excellent
compliance. The fact that there were no study dropouts
further indicates the tolerability of the study treatments.
No adverse events were reported.
Discussion
The effect of dietary fiber on cholesterol metabolism has
been studied extensively (Keys et al., 1960; Burkitt et al.,
1974; Trowell, 1975), even if results between studies on the
effects of different kinds of fibers on LDL-cholesterol concen-
trations are variable (Anderson, 1987; McIntosh et al., 1991;
Talati et al., 2009). This variability may be due to several
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factors, such as fiber intake, baseline serum cholesterol
concentrations, mode of administration, food matrix, and
solubility or molecular weight of the fiber. This study was
dedicated to comparatively studying, by a crossover clinical
trial, the effects of two different kinds of dietary fibers on
lipidemic pattern in mildly hypercholesterolemic subjects.
To our knowledge, this is the first time that water-soluble
fiber beta-glucans and non-soluble fiber rice bran have been
Table 3 Cardiovascular risk variables at screening and after adaptation period
Parameter At screening a After adaptation period a Mean change (95% CI) P-value
LDL-cholesterol (mmol/l) 4.17 (0.56) 3.64 (0.86) 0.53 (0.79 to 0.26) o0.001
Total cholesterol (mmol/l) 6.44 (0.55) 5.90 (0.68) 0.54 (0.75 to 0.33) o0.001
HDL-cholesterol (mmol/l) 1.52 (0.42) 1.61 (0.49) 0.09 (0.07 to 0.24) 0.28
Total cholesterol/HDL-cholesterol 4.58 (1.45) 4.03 (1.32) 0.55 (0.88 to 0.22) 0.002
LDL-cholesterol/HDL-cholesterol 3.00 (1.06) 2.55 (1.09) 0.45 (0.75 to 0.15) 0.005
Apolipoprotein A1 (g/l) 1.31 (0.31) 1.15 (0.23) 0.16 (0.23 to 0.09) o0.001
Apolipoprotein B (g/l) 1.27 (0.20) 1.31 (0.23) 0.04 (0.04 to 0.12) 0.33
Apolipoprotein A1/apolipoprotein B 1.06 (0.33) 0.91 (0.27) 0.15 (0.21 to 0.09) o0.001
Triglycerides (mmol/l) 1.63 (0.99) 1.42 (0.82) 0.21 (0.50 to 0.09) 0.16
Glucose (mmol/l) 5.21 (0.36) 5.04 (0.38) 0.17 (0.30 to 0.05) 0.009
Abbreviations: CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
aMean (s.d.).
Table 2 Nutritional intakes of volunteers’ previous enrolment in the crossover clinical trial and nutritional composition of total diet and of foods enriched
with beta-glucans or rice bran and of other nutrients consumed daily by the volunteers during the different periods of the crossover clinical trial
Pretreatment
period a
Periods 1 and
3 total diet a
Beta-glucans
period a
Rice bran
period a
Total
diet
Foods enriched with
beta-glucans
Total
diet
Foods enriched
with rice bran
Energy (kJ) 11058.73 (780.87) 11181.87 (754.56) 10972.3 (391.63) 3972.88 11166.69 (688.47) 4167.58
Protein (g) 96.67 (18.17) 79.41 (6.72) 85.81 (6.89) 29.49 88.95 (6.55) 33.07
(% energy) 14.72 (3.11) 11.89 (0.74) 12.95 (0.79) — 13.38 (0.71) —
Fat (g) 81.77 (16.49) 73.91 (5.08) 78.29 (3.39) 12.81 80.60 (3.53) 17.37
(% energy) 27.81 (5.17) 24.92 (1.27) 26.65 (1.73) — 27.32 (1.35) —
Saturated fatty acids (%) 9.58 (2.92) 6.09 (1.05) 6.22 (1.56) — 6.55 (1.65) —
Carbohydrate (g) 404.16 (62.88) 447.32 (35.27) 406.24 (31.38) 170.74 397.96 (34.04) 166.21
(%) 57.28 (7.61) 62.74 (1.31) 57.44 (1.53) — 56.03 (1.59) —
Complex (g) 326.04 (57.28) 357.62 (35.98) 302.44 (33.20) 154.29 305.73 (41.93) 155.29
(%) 46.18 (6.97) 50.11 (2.08) 42.72 (2.76) — 42.16 (2.59) —
Simple (g) 78.01 (20.27) 89.70 (9.44) 103.79 (8.48) 16.44 98.16 (8.60) 10.92
(%) 11.10 (2.93) 12.63 (1.55) 14.72 (1.35) — 13.87 (1.35) —
Dietary fiber (g) 19.73 (3.03) 26.74 (3.16) 39.33 (3.33) 17.74 45.70 (3.49) 24.29
Soluble (g) 7.01 (1.10) 9.12 (0.91) 13.74 (0.93) 6.98 10.36 (0.95) 3.69
Insoluble (g) 12.69 (2.21) 17.62 (2.44) 24.89 (2.15) 10.76 34.63 (2.24) 20.60
Beta-glucans (g) — 5.99 5.99 — —
Cholesterol (mg) 287 (89) 275 (93) 279 (99) 281 (93)
aMean (s.d.); Nutritional evaluation from Carnovale E, Marletta L: ‘Tabelle di composizione degli alimenti’, Istituto Nazionale della Nutrizione, Roma, 1997 and from
the results of the laboratory assessment, according to the following methods: Proteins: Protein determination through acid-catalyzed mineralization, with alkaline
ammoniacal nitrogen. The ammonia produced is determined through titrimetric measuring. The value of ammonia obtained is multiplied for the factor 6.25 (ISO
937-1978 (E), AOAC Official Method ‘Nitrogen in Beer’ 950.53, AOAC Official Method ‘Nitrogen in Liquid eggs’ 932.08, AOAC Official Method ‘Nitrogen in milk’
991.20, AOAC Official Method ‘Nitrogen in wines’ 920.70). Fats: Determination by gravimetric, with acid hydrolysis of the sample and subsequent extraction with
petroleum ether in Soxhlet (ISTISAN 1996/34, pp 41–43). Fatty acids: The methyl esters obtained by transmethylation of fatty material are separated in capillary gas
chromatography column (Method NGD C2—1989; Method NGC C41/42—1976, Regulation (CEE) No. 2568/91; Method COI/T.20/Doc. No. 24—2001,
Regulation (CE) No. 796/2002). Carbohydrates: Value obtained by difference to 100, with known values of water, ash, fat, protein and dietary fibers content in the
food. Simple sugars: The sugars are extracted with hot water, clarified with the Carez reagent and silanized. The revelation of the trimethylsilyl ethers is carried out in
gas chromatography (GC-FID) on a capillary column. Dietary fibers: Gravimetric determination—with enzymatic precipitation of soluble fiber with hot ethanol
(AOAC 985.29 and 17th 2003).
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compared with regard to their efficacy on lipid pattern in a
crossover study. The studied fiber sources, namely, beta-
glucans from barley and bran from rice, were selected from
among cereals because of their particular hypocholesterole-
mic properties, the mechanisms of action of which on lipidic
pattern are very different. Beta-glucans are water-soluble
dietary fibers, having gel-forming properties that cause
effects on lipid pattern (Marlett et al., 1994; Drozdowski
et al., 2010), whereas rice bran is a water-insoluble fiber with
active components having a cholesterol-lowering effect
(Qureshi et al., 2000; Wilson et al., 2007).
The first result of this trial is that the subjects after the
3-week adaptation period with rice bran-enriched foods
experienced significant reductions in blood LDL-cholesterol,
total cholesterol, apo A-I, total/HDL-cholesterol and glucose,
in agreement with previous large studies (Keys et al., 1960;
Burkitt et al., 1974; Trowell, 1975; Cheng et al., 2010). The
mean fiber intake of the volunteers before the start of the
study (12±2g per day) was lower than the recommended
daily intake (30 g per day), in agreement with previous
studies on the adherence of the general Italian population to
the recommendations for correct nutritional behavior
(Avellone et al., 1997; Rivellese et al., 2008). The increase in
the intake of fiber, including water-insoluble fiber, such as
rice bran, caused a significant cholesterol-lowering effect.
These results show that therapeutic dietetic changes remain
an essential modality in clinical management of hyper-
cholesterolemia (Grundy et al., 2004).
Moreover, the comparison of the treatment effects clearly
indicated that beta-glucans fiber exhibited the most marked
influence on cholesterolemia: in the study, participants
receiving beta-glucan-enriched foods had statistically signi-
ficant reductions in LDL-cholesterol (0.33mmol/l) and
total cholesterol (0.31mmol/l), compared with participants
receiving rice bran-enriched foods. In reality, the therapy of
mild hypercholesterolemia is lacking. The use of statins, the
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibi-
tors that are the mainstay in the pharmacological manage-
ment of dyslipidemia, has been reserved in patients with
at least one other risk of CVD. Moreover, the unwanted side
effects of statins are numerous, frequent and dangerous
(Kostapanos et al., 2010). On the contrary, the consumption
of foods enriched in beta-glucans has no known side effects,
and, moreover, permits a higher intake per serving with a
minimum decrease in palatability (Jenkins et al., 2002). The
food products used in this study were developed taking into
consideration the problem of compliance. Rice bread and
pasta, sauces and soups enriched with beta-glucans are ready
to use and are hence easy to eat. Moreover, these foods are
well known to contain adequate amounts of beta-glucans
Table 4 Comparison of treatments on cardiovascular risk variables, the mental component summary and physical component summary of SF-36 score
and Wexner score for constipation at baseline and at the end of intervention
Parameter Treatment Baseline a Final, after 4 weeks
of intervention
periods a
Mean change
(95% CI)
P-value for
change
Treatment
effect b
Treatment
comparison
P-value
LDL-cholesterol (mmol/l) Beta-glucans 3.84 (0.64) 3.51 (0.66) 0.33 (0.58 to 0.08) 0.012 0.21 (0.40 to 0.02) 0.033
Rice bran 3.68 (0.87) 3.63 (0.63) 0.04 (0.29 to 0.19) 0.66
Total cholesterol (mmol/l) Beta-glucans 6.14 (0.53) 5.83 (0.46) 0.30 (0.47 to 0.14) 0.001 0.34 (0.47 to 0.20) o0.001
Rice bran 5.99 (0.72) 6.07 (0.57) 0.08 (0.06 to 0.23) 0.25
HDL-cholesterol (mmol/l) Beta-glucans 1.65 (0.41) 1.70 (0.49) 0.05 (0.13 to 0.23) 0.59 0.01 (0.10 to 0.11) 0.91
Rice bran 1.65 (0.46) 1.68 (0.49) 0.03 (0.09 to 0.16) 0.58
Total cholesterol/HDL-cholesterol Beta-glucans 3.94 (1.01) 3.76 (1.26) 0.18 (0.57 to 0.21) 0.35 0.18 (0.38 to 0.01) 0.07
Rice bran 3.96 (1.32) 3.96 (1.46) 0.00 (0.37 to 0.37) 1.00
LDL-cholesterol/HDL-cholesterol Beta-glucans 2.51 (0.84) 2.33 (1.05) 0.18 (0.54 to 0.17) 0.30 0.11 (0.26 to 0.04) 0.17
Rice bran 2.44 (1.03) 2.38 (1.07) 0.07 (0.36 to 0.23) 0.64
Apolipoprotein A1 (g/l) Beta-glucans 1.15 (0.22) 1.13 (0.21) 0.02 (0.08 to 0.05) 0.61 0.06 (0.13 to 0.01) 0.10
Rice bran 1.12 (0.21) 1.15 (0.24) 0.04 (0.04 to 0.11) 0.31
Apolipoprotein B (g/l) Beta-glucans 1.23 (0.17) 1.10 (0.12) 0.14 (0.09 to 0.18) o0.001 0.04 (0.09 to 0.01) 0.12
Rice bran 1.18 (0.21) 1.11 (0.11) 0.07 (0.01 to 0.14) 0.03
Apolipoprotein A1/apolipoprotein B Beta-glucans 0.95 (0.23) 1.06 (0.29) 0.11 (0.18 to 0.04) 0.004 0.02 (0.06 to 0.10) 0.58
Rice bran 0.98 (0.28) 1.06 (0.30) 0.08 (0.13 to 0.03) 0.005
Triglycerides (mmol/l) Beta-glucans 1.41 (0.72) 1.36 (0.61) 0.05 (0.27 to 0.18) 0.67 0.19 (0.48 to 0.10) 0.20
Rice bran 1.38 (0.84) 1.55 (0.85) 0.17 (0.16 to 0.50) 0.29
Glucose (mmol/l) Beta-glucans 4.97 (0.48) 4.82 (0.56) 0.15 (0.33 to 0.03) 0.10 0.08 (0.29 to 0.13) 0.44
Rice bran 4.88 (0.36) 4.81 (0.46) 0.08 (0.27 to 0.11) 0.42
SF-36 physical component summary Beta-glucans 52.35 (8.13) 53.32 (7.11) 0.97 (1.06 to 3.00) 0.33 0.89 (0.17 to 1.96) 0.10
Rice bran 52.35 (8.13) 54.25 (7.20) 1.90 (0.17 to 3.62) 0.032
SF-36 mental component summary Beta-glucans 53.87(10.88) 56.47 (8.83) 2.60 (0.27 to 4.94) 0.03 0.31 (1.39 to 0.77) 0.57
Rice bran 53.87(10.88) 56.17 (8.88) 2.30 (0.33 to 4.93) 0.08
Wexner score for constipation Beta-glucans 2.46 (2.93) 2.29 (2.90) 0.17 (0.55 to 0.22) 0.38 0.55 (0.08 to 1.17) 0.09
Rice bran 2.65 (2.35) 1.91 (2.48) 0.74 (0.20 to 1.28) 0.01
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; SF-36, Short-Form 36-Item Health Survey.
aMean (s.d.).
bMean difference between final values (95% CI) adjusted for baseline values of each period and for period effect.
Bold entries emphasize that this result concerns the primary end point.
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and rice bran because the analysis for the amount of fibers
has been carried out in finite products. Finally, another
possible advantage of beta-glucan-enriched foods compared
with drug therapy is lower costs.
A limitation of the study is that it was conducted
exclusively in a group of men. The choice of including only
men in the study accrued from two considerations: (1) hyper-
cholesterolemia is a disease more commonly found in male
subjects than in female subjects; and (2) many confounding
factors related to hormonal status (cycle time, pre-, peri- or
post-menopausal phase) may be present in women. Further
studies are needed to collect evidence in women.
As regards health-related quality of life, there were no
significant differences for the SF-36 scores; the results of this
study showed that general health parameters in each group
did not differ from each other at baseline and did not change
appreciably during the course of the study. A significant
change in the SF-36 was not expected; it was included in this
study to rule out any adverse effects on general health
functioning in either group.
In conclusion, health practitioners should feel comfortable
recommending barley beta-glucan-enriched foods to their
patients with mild hypercholesterolemia to help reduce total
and LDL-cholesterol concentrations. It is well established
that an elevated LDL-cholesterol concentration is a risk
factor for CVD (National Cholesterol Educational Program,
Adult Treatment Panel III, 2002). Studies have shown that,
for each milligram per deciliter (0.0026mmol/l) reduction in
a patient’s LDL-cholesterol level, their relative risk of having
a coronary heart disease event is decreased by 1%; therefore,
this reduction in LDL cholesterol observed with food
enriched with beta-glucans is likely to be clinically signifi-
cant as well (Grundy et al., 2004). Moreover, such changes in
cardiovascular risk factors, when applied to the whole
population, have significant potential for reducing CVD
(Kottke et al., 1985).
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